Education
About Us
Working with TipRanks
Follow Us
Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
GUFICBIO Stock Chart & Stats
₹338.15
-₹9.05(-1.92%)
At close: 4:00 PM EST
₹338.15
-₹9.05(-1.92%)
Day’s Range― - ―
52-Week Range₹273.10 - ₹409.00
Previous CloseN/A
Volume28.80K
Average Volume (3M)2.36K
Market Cap
₹28.24B
Enterprise Value₹30.88B
Total Cash (Recent Filing)₹290.22M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)56.4
Beta0.93
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.03%
Share Statistics
EPS (TTM)1.24
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-2.39
Price to Book (P/B)5.63
Price to Sales (P/S)4.13
P/FCF Ratio124.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion from 2020–2025 indicates durable demand for the company’s formulations across markets. Continued top-line growth supports scale economies, reinvestment in capacity and product development, and provides a structural base for margin and cash-flow improvement over months.
Operational Efficiency / MarginsSolid gross and EBIT margins reflect persistent cost control and manufacturing efficiency, which are structural strengths in pharmaceutical production. Margin resilience helps absorb pricing pressure and supports profitability even if net items fluctuate, aiding multi-month operational stability.
Equity Strength / Capital StructureA steady rise in shareholders’ equity and a healthy equity ratio provide long-term financing flexibility, lower insolvency risk, and capacity to fund capex or regulatory compliance. This structural capital strength supports strategic initiatives and cushions operational headwinds over the medium term.
Bears Say
Cash Flow VolatilityVariable free cash flow conversion is a durable concern because it constrains the firm’s ability to self-fund capex, R&D, or pay down debt. Recurrent swings in cash generation increase reliance on external financing and raise execution risk for multi-month growth or margin initiatives.
Elevated LeverageA moderately high debt-to-equity ratio is a structural vulnerability: higher fixed interest costs reduce earnings resilience and financial flexibility. In downturns or slower revenue periods this leverage can pressure liquidity and limit ability to invest in capacity or product development over several months.
Earnings / Profitability VolatilityMaterial negative EPS growth and net-profit margin fluctuations point to underlying volatility in profitability drivers (costs, interest, one-offs). Persistent earnings variability undermines sustainable cash generation and complicates planning for reinvestment, dividend policy, and debt servicing over the medium term.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹273.10 and its highest was ₹409.00 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹28.24B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is May 29, 2026 which is in 87 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on Feb 13, 2026. The company reported ₹1.239 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.239.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹1.239 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.022%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―